273 related articles for article (PubMed ID: 16109773)
21. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
Cuenco GM; Nucifora G; Ren R
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
[TBL] [Abstract][Full Text] [Related]
22. Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia.
Lopingco MC; Perkins AS
Curr Top Microbiol Immunol; 1996; 211():211-22. PubMed ID: 8585952
[TBL] [Abstract][Full Text] [Related]
23. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
[TBL] [Abstract][Full Text] [Related]
24. Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice.
Louz D; van den Broek M; Verbakel S; Vankan Y; van Lom K; Joosten M; Meijer D; Löwenberg B; Delwel R
Leukemia; 2000 Nov; 14(11):1876-84. PubMed ID: 11069022
[TBL] [Abstract][Full Text] [Related]
25. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome.
Dickstein J; Senyuk V; Premanand K; Laricchia-Robbio L; Xu P; Cattaneo F; Fazzina R; Nucifora G
Proc Natl Acad Sci U S A; 2010 May; 107(21):9783-8. PubMed ID: 20448201
[TBL] [Abstract][Full Text] [Related]
26. Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.
Bard-Chapeau EA; Szumska D; Jacob B; Chua BQ; Chatterjee GC; Zhang Y; Ward JM; Urun F; Kinameri E; Vincent SD; Ahmed S; Bhattacharya S; Osato M; Perkins AS; Moore AW; Jenkins NA; Copeland NG
PLoS One; 2014; 9(2):e89397. PubMed ID: 24586749
[TBL] [Abstract][Full Text] [Related]
27. Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.
Nishikawa S; Arai S; Masamoto Y; Kagoya Y; Toya T; Watanabe-Okochi N; Kurokawa M
Blood; 2014 Dec; 124(24):3587-96. PubMed ID: 25298035
[TBL] [Abstract][Full Text] [Related]
28. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.
Ott MG; Schmidt M; Schwarzwaelder K; Stein S; Siler U; Koehl U; Glimm H; Kühlcke K; Schilz A; Kunkel H; Naundorf S; Brinkmann A; Deichmann A; Fischer M; Ball C; Pilz I; Dunbar C; Du Y; Jenkins NA; Copeland NG; Lüthi U; Hassan M; Thrasher AJ; Hoelzer D; von Kalle C; Seger R; Grez M
Nat Med; 2006 Apr; 12(4):401-9. PubMed ID: 16582916
[TBL] [Abstract][Full Text] [Related]
29. Prdm3 and Prdm16 cooperatively maintain hematopoiesis and clonogenic potential.
McGlynn KA; Sun R; Vonica A; Rudzinskas S; Zhang Y; Perkins AS
Exp Hematol; 2020 May; 85():20-32.e3. PubMed ID: 32437910
[TBL] [Abstract][Full Text] [Related]
30. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
31. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro.
Senyuk V; Li D; Zakharov A; Mikhail FM; Nucifora G
Cancer Res; 2005 Sep; 65(17):7603-11. PubMed ID: 16140925
[TBL] [Abstract][Full Text] [Related]
32. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
33. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.
Lavau C; Szilvassy SJ; Slany R; Cleary ML
EMBO J; 1997 Jul; 16(14):4226-37. PubMed ID: 9250666
[TBL] [Abstract][Full Text] [Related]
34. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression.
Huang S; Shao G; Liu L
J Biol Chem; 1998 Jun; 273(26):15933-9. PubMed ID: 9632640
[TBL] [Abstract][Full Text] [Related]
35. The EVI1 gene in myeloid leukemia.
Nucifora G
Leukemia; 1997 Dec; 11(12):2022-31. PubMed ID: 9447815
[TBL] [Abstract][Full Text] [Related]
36. Phenotyping of Evi1, Evi11/Cb2, and Evi12 transformed leukemias isolated from a novel panel of cas-Br-M murine leukemia virus-infected mice.
Joosten M; Valk PJ; Vankan Y; de Both N; Löwenberg B; Delwel R
Virology; 2000 Mar; 268(2):308-18. PubMed ID: 10704339
[TBL] [Abstract][Full Text] [Related]
37. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.
Modlich U; Bohne J; Schmidt M; von Kalle C; Knöss S; Schambach A; Baum C
Blood; 2006 Oct; 108(8):2545-53. PubMed ID: 16825499
[TBL] [Abstract][Full Text] [Related]
38. EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages.
Steinleitner K; Rampetsreiter P; Köffel R; Ramanathan G; Mannhalter C; Strobl H; Wieser R
Anticancer Res; 2012 Nov; 32(11):4883-9. PubMed ID: 23155256
[TBL] [Abstract][Full Text] [Related]
39. Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation.
Wimmer K; Vinatzer U; Zwirn P; Fonatsch C; Wieser R
Biochem Biophys Res Commun; 1998 Nov; 252(3):691-6. PubMed ID: 9837768
[TBL] [Abstract][Full Text] [Related]
40. Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Löwenberg B; Delwel R
Exp Hematol; 2003 Nov; 31(11):1066-72. PubMed ID: 14585371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
